<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362490">
  <stage>Registered</stage>
  <submitdate>14/05/2012</submitdate>
  <approvaldate>31/10/2012</approvaldate>
  <actrnumber>ACTRN12612001155886</actrnumber>
  <trial_identification>
    <studytitle>Investigating the role of transcranial direct current stimulation for pain relief in fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome patients</studytitle>
    <scientifictitle>Investigating the role of transcranial direct current stimulation for pain relief in fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome patients - Deakin University</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
    <secondaryid>N/A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fibromyalgia Syndrome</healthcondition>
    <healthcondition>Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>transcranial direct current stimulation (tDCS) will be administered (.8mA) 20 mins daily for 15 consecutive days (not including weekends). The current will be gradually switched on and off over a 30sec period (ramped) at the start and end of the stimulation period.</interventions>
    <comparator>Sham tDCS - Current will be ramped on and then the tDCS machine will switch itself off after 30 secs (though the display will remain the same to allow for double-blinding).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain assessed by visual analog scale and the McGill Pain Questionnaire</outcome>
      <timepoint>2 weeks prior through to 3 months post intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Transcranial magnetic stimulation - 5 pulses (intensity determined by individual's motor threshold) will be applied to M1 in order to determine changes in neural excitation/inhibition from tDCS.</outcome>
      <timepoint>2 weeks prior through to 3 months post intervention.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Fatigue assessed by Chalder Fatigue Scale and Fatigue Severity Scale</outcome>
      <timepoint>2 weeks prior through to 3 months post intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>General illness symptoms assessed by checklist</outcome>
      <timepoint>2 weeks prior through to 3 months post intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Daily functioning assessed by the Fibromyalgia Impact Questionnaire</outcome>
      <timepoint>2 weeks prior through to 3 months post intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Depression assessed by the Depression Anxiety Stress Scales and Inventory of Depressive Symptomatology</outcome>
      <timepoint>2 weeks prior through to 3 months post intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sleep assessed by Pittsburgh Sleep Questionnaire</outcome>
      <timepoint>2 weeks prior through to 3 months post intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anxiety assessed by Depression Anxiety Stress Scales</outcome>
      <timepoint>2 weeks prior through to 3 months post intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participants will be verbally asked whether they think they received the sham or active tDCS</outcome>
      <timepoint>At the conclusion of the 15 days of stimulation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome or fibromyalgia syndrome by medical practitioner associated with the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy, neurological injury</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/11/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>32</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason>Other reasons/comments</withdrawnreason>
    <withdrawnreasonother>Needed to conduct pilot study re: protocol.</withdrawnreasonother>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Deakin University</primarysponsorname>
    <primarysponsoraddress>221 Burwood Hwy
Burwood, Vic, 3125</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Deakin University</fundingname>
      <fundingaddress>221 Burwood Hwy
Burwood, Vic, 3125</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to seek whether longer treatment protocols than previously applied in research will result in longer-lasting and stronger improvements in pain relief in ME/CFS and FMS.  The study also seeks to investigate whether pain reduction is associated with improvements in other chronic illness symptoms.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Deakin University Human Research Ethics Commitee</ethicname>
      <ethicaddress>Deakin University
221 Burwood Hwy
Burwood, Vic, 3125</ethicaddress>
      <ethicapprovaldate>12/07/2012</ethicapprovaldate>
      <hrec>2012-084</hrec>
      <ethicsubmitdate>16/05/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Hannah Bereznicki</name>
      <address>Cognitive and Exercise Neuroscience Unit
Deakin University
221 Burwood Hwy
Burwood, Vic, 3125</address>
      <phone>+61 3 92517224</phone>
      <fax />
      <email>hannah.bereznicki@deakin.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Hannah Bereznicki</name>
      <address>Cognitive and Exercise Neuroscience Unit
Deakin University
221 Burwood Hwy
Burwood, Vic, 3125</address>
      <phone>+61 3 92517224</phone>
      <fax />
      <email>hannah.bereznicki@deakin.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Hannah Bereznicki</name>
      <address>Cognitive and Exercise Neuroscience Unit
Deakin University
221 Burwood Hwy
Burwood, Vic, 3125</address>
      <phone>+61 3 92517224</phone>
      <fax />
      <email>hannah.bereznicki@deakin.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Hannah Bereznicki</name>
      <address>Deakin University 
221 Burwood Hwy 
Burwood, Vic, Aus </address>
      <phone>+61 3 5227 8715</phone>
      <fax />
      <email>hannah.bereznicki@deakin.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>